This is exemplified by the 21-year follow-up of the Steno diabetes study; specifically, appropriate management of systolic blood pressure, glycated hemoglobin (A1C), and low-density lipid (LDL) cholesterol resulted in a 20 percent absolute risk reduction at 13 years, a benefit that was persistent at 21 years [36, 37].